Palatin Technologies, Inc. (PTN) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 02/09/22
Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye DiseasePRNewsWire • 12/28/21
Here's Why Palatin Technologies, Inc. (PTN) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/06/21
Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific PeptidePRNewsWire • 11/30/21
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate UpdatePRNewsWire • 11/15/21
Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021PRNewsWire • 11/10/21
Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual MeetingPRNewsWire • 10/22/21
Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 09/29/21
Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate UpdatePRNewsWire • 09/29/21
Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual MeetingPRNewsWire • 09/27/21
Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021PRNewsWire • 09/24/21